AndreaBozzo/ceres-open-data-index huggingface dataset:
2013 CMHS Uniform Reporting System (URS) Tables for Massachusetts

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Massachusetts for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Philadelphia-Camden-Wilmington, PA-NJ-DE-MD metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Philadelphia-Camden-Wilmington metro area, Pennsylvania, and the U.S. overall.
2019-2020 National Survey on Drug Use and Health: Other Sources of State-Level Data

State estimates for these years are no longer available due to methodological concerns with combining 2019 and 2020 data. We apologize for any inconvenience or confusion this may causeBecause of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the two years could be misleading.For more detail on this decision, see the 2019-2020state data page.
Molecular distinction amongst varieties of Mulberry using RAPD and DAMD profiles

Background
          Mulberry trees are the most important host for rearing mulberry silkworms in sericulture. Improved varieties of mulberry tree have been developed through traditional breeding procedures. Not much work, however, has been carried out on the molecular characterization of these varieties. Random Amplified Polymorphic DNA (RAPD) and Directed Amplification of Minisatellite DNA (DAMD) methods based on Polymerase Chain Reaction are important tools to analyze genetic diversity of mulberries. These have been used to determine variation amongst nine varieties of Morus spp. maintained at Banthra Research Station of National Botanical Research Institute, Lucknow.
        
        
          Results and Discussion
          The varieties were analyzed using 23 arbitrary sequence decamer primers for RAPD, and 3 minisatellite core sequence primers for DAMD reactions. The RAPD and DAMD band data, (a total of 200 bands), were used to determine the pair wise distances according to Jaccard's algorithm. From these distance values Neighbour Joining (NJ) analyses were carried out separately for the RAPD and the DAMD data. The triploid varieties were found to be most similar to each other using RAPD analysis, while the varieties S13 and S34 were more similar using DAMD analysis. Nearly 85% of the RAPD bands and 91% of the DAMD bands were polymorphic across the nine varieties.
        
        
          Conclusions
          The mulberry varieties could be distinguished by their RAPD and DAMD profiles. As many as five RAPD primers and one DAMD primer generated profiles that can together differentiate all the nine varieties in terms of unique bands.
Patent AT-E401093-T1: [Translated] EXTRACTS, ACTIVE INGREDIENTS AND PHARMACEUTICAL PREPARATIONS WITH ANTIDIABETIC PROPERTIES AND THEIR USE

The present invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia and having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption

The contribution of osteoclasts to the process of bone loss in inflammatory arthritis has recently been demonstrated. Studies in osteoclast biology have led to the identification of factors responsible for the differentiation and activation of osteoclasts, the most important of which is the receptor activator of NF-κB ligand/osteoclast differentiation factor (RANKL/ODF), a tumor necrosis factor (TNF)-like protein. The RANKL/ODF receptor, receptor activator of NF-κB (RANK), is a TNF-receptor family member present on both osteoclast precursors and mature osteoclasts. Like other TNF-family receptors and the IL-1 receptor, RANK mediates its signal transduction via TNF receptor-associated factor (TRAF) proteins, suggesting that the signaling pathways activated by RANK and other inflammatory cytokines involved in osteoclast differentiation and activation are interconnected.
Compound 529534: Phenanthrene, 3,6-difluoro

Chemical compound data from PubChem database. IUPAC Name: 3,6-difluorophenanthrene. Molecular Formula: C14H8F2. Molecular Weight: 214.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

Background
          Flavopiridol, a flavonoid currently in cancer clinical trials, inhibits cyclin-dependent kinases (CDKs) by competitively blocking their ATP-binding pocket. However, the mechanism of action of flavopiridol as an anti-cancer agent has not been fully elucidated.
        
        
          Results
          Using DNA microarrays, we found that flavopiridol inhibited gene expression broadly, in contrast to two other CDK inhibitors, roscovitine and 9-nitropaullone. The gene expression profile of flavopiridol closely resembled the profiles of two transcription inhibitors, actinomycin D and 5,6-dichloro-1-β-D-ribofuranosyl-benzimidazole (DRB), suggesting that flavopiridol inhibits transcription globally. We were therefore able to use flavopiridol to measure mRNA turnover rates comprehensively and we found that different functional classes of genes had distinct distributions of mRNA turnover rates. In particular, genes encoding apoptosis regulators frequently had very short half-lives, as did several genes encoding key cell-cycle regulators. Strikingly, genes that were transcriptionally inducible were disproportionately represented in the class of genes with rapid mRNA turnover.
        
        
          Conclusions
          The present genomic-scale measurement of mRNA turnover uncovered a regulatory logic that links gene function with mRNA half-life. The observation that transcriptionally inducible genes often have short mRNA half-lives demonstrates that cells have a coordinated strategy to rapidly modulate the mRNA levels of these genes. In addition, the present results suggest that flavopiridol may be more effective against types of cancer that are highly dependent on genes with unstable mRNAs.
Role of arginine and its methylated derivatives in cancer biology and treatment

Both L-arginine supplementation and deprivation influence cell proliferation. The effect of high doses on tumours is determined by the optical configuration: L-arginine is stimulatory, D-arginine inhibitory. Arginine-rich hexapeptides inhibited tumour growth. Deprivation of L-arginine from cell cultures enhanced apoptosis. The pro-apoptotic action of NO synthase inhibitors, like NG-monomethyl-L-arginine, is manifested through inhibition of the arginase pathway. NG-hydroxymethyl-L-arginines caused apoptosis in cell cultures and inhibited the growth of various transplantable mouse tumours. These diverse biological activities become manifest through formaldehyde (HCHO) because guanidine group of L-arginine in free and bound form can react rapidly with endogenous HCHO, forming NG-hydroxymethylated derivatives. L-arginine is a HCHO capturer, carrier and donor molecule in biological systems. The role of formaldehyde generated during metabolism of NG-methylated and hydroxymethylated arginines in cell proliferation and death can be shown. The supposedly anti-apoptotic homozygous Arg 72-p53 genotype may increase susceptibility of some cancers. The diverse biological effects of L-arginine and its methylated derivatives call for further careful studies on their possible application in chemoprevention and cancer therapy.
Compound 529450: 2-Hydroxyguaia-1(10),11-dien-15-oic acid

Chemical compound data from PubChem database. IUPAC Name: 2-(2-hydroxy-3-methyl-8-methylidene-2,4,5,6,7,8a-hexahydro-1H-azulen-5-yl)propanoic acid. Molecular Formula: C15H22O3. Molecular Weight: 250.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hydromorphone hydrochloride

Hydromorphone Hydrochloride is a generic prescription opioid medication used to manage severe pain. It comes as oral tablets in strengths of 2 mg, 4 mg, and 8 mg, manufactured by Aurolife Pharma, LLC. As a Schedule II controlled substance, it has a high potential for abuse and addiction. This information was generated using AI and is provided for informational and research purposes only.
data.hrsa.gov (HRSA Data Warehouse)

<p>DATA.HRSA.GOV is the go-to source for data, dashboards, maps, reports, locators, APIs and downloadable data files on HRSA's public health programs, including:</p>
<ul>
<li>HRSA-funded Health Center grants, grantees, sites, and related primary care programs</li>
<li>Health Professional Shortage Areas (HPSA) and Medically Underserved Areas/Populations (MUA/P)</li>
<li>Ryan White HIV/AIDS services, grantees, and providers</li>
<li>Maternal and Child Health grants (Title V, Home Visiting, Healthy Start)</li>
<li>National Health Service Corps (NHSC), Nurse Corps, and other workforce loan repayment/scholarship programs</li>
<li>Grants for workforce training programs in medicine, nursing, dentistry, and public health</li>
<li>Grants for rural health programs</li>
<li>Organ donation</li>
</ul>
<p>DATA.HRSA.GOV allows you to search by topic area, by geography, and by tool.</p>
Compound 527240: Vetiselinenol

Chemical compound data from PubChem database. IUPAC Name: 2-(4a-methyl-8-methylidene-1,4,5,6,7,8a-hexahydronaphthalen-2-yl)propan-1-ol. Molecular Formula: C15H24O. Molecular Weight: 220.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525852: N,N-Dimethyl-2-phenyl-N'-(3-nitrophenyl)-acetamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(3-nitrophenyl)-2-phenylethanimidamide. Molecular Formula: C16H17N3O2. Molecular Weight: 283.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2009 Mental Health National Outcome Measures (NOMS): CMHS Uniform Reporting System

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2009. The URS is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State mental health authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures, providing an overview of state mental health delivery systems.
Compound 526565: 11,19-Dimethylpentatriacontane

Chemical compound data from PubChem database. IUPAC Name: 11,19-dimethylpentatriacontane. Molecular Formula: C37H76. Molecular Weight: 521.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2013 NSDUH Illicit Drug Use Tables (Standard Errors and P Values) - 1.1 to 1.92

These detailed tables present standard errors for illicit drug use totals and prevalence estimates from the 2013 National Survey on Drug Use and Health (NSDUH). Illicit drugs include marijuana, cocaine, crack, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type psychotherapeutics, including pain relievers, tranquilizers, stimulants, and sedatives. Standard errors are provided for lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, and geographic area. Standard errors are provided for both 2013 and 2012.
Compound 527390: 22-Methyl-tritriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 23-methyltetratriacontanenitrile. Molecular Formula: C35H69N. Molecular Weight: 503.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530543: 3-Cyclopentylpropionic acid, hexyl ester

Chemical compound data from PubChem database. IUPAC Name: hexyl 3-cyclopentylpropanoate. Molecular Formula: C14H26O2. Molecular Weight: 226.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401530-T1: [Translated] LIGHTING DEVICE

A lighting device (30) having a housing (12) which includes a lamp means, a battery housing to receive at least one battery and a switch means to open and close a circuit between said lamp means and terminals of said at least one battery when located in said housing. Said lighting device includes a lanyard (110, 112) attached to said housing (12) characterised by said lanyard having a proximal end attached to said housing (12) and a distal end, whereby said distal end or a portion of said lanyard (110, 112) is adapted to be releasably attached to said housing (12).
Indicators for 2015A

For January 1, 2015 through March 31, 2015, the PFS update was set at 0.0 percent by the Protecting Access to Medicare Act. After applying the budget neutrality adjustment of 0.9981, the conversion factor for January 1, 2015, through March 31, 2015 is $35.7547. Under the provisions of current law regarding the SGR, the conversion factor will change to $28.1872 on April 1, 2015 in the absence of Congressional action. In addition, the geographic practice cost index work floor of 1.0 expires on March 31, 2015 in the absence of legislative action.
Weekly Differences in Cumulative RSV Vaccination Coverage Among Adults 75 and Older and 60–74 Years with High-Risk Conditions Ever Vaccinated with RSV Vaccine, Overall, by Selected Demographics

• Weekly Cumulative RSV Vaccination Coverage and Intent Among Adults 75 Years and Older and 60─74 Years with High Risk Conditions Ever Vaccinated with RSV Vaccine by Demographic Characteristics and Jurisdiction 
• Weekly estimates of RSV vaccination coverage and intent among adults 75 years and older and 60─74 years with high risk conditions are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/)
• In June 2023, the Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine, using shared clinical decision-making. In June 2024, the ACIP voted to recommend a single dose of RSV vaccine for all adults 75 years and older and adults 60–74 years who are at increased risk for severe RSV disease. The data below captures ever receiving a dose of an RSV vaccine by adults 60 years and older.
The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia

Background
          Finasteride, a 5 alpha reductase inhibitor, is an established treatment for benign prostatic hyperplasia. The recommended dosage is 5 mg a day, however case reports have show effectiveness with lower doses. The objective of the current study was to determine in men with benign prostatic hyperplasia, previously treated for at least one year with finasteride 5 mg daily, if they will maintain subjective and objective improvements in urinary obstruction when treated with 2.5 mg of finasteride daily for one year.
        
        
          Methods
          In an open label, prospective study, 40 men with benign prostatic hyperplasia, previously treated for at least one year with 5 mg of finasteride, took 2.5 mg of finasteride daily for one year. Measurements included AUA symptom score, maximum flow rate, voided volume and PSA.
        
        
          Results
          There were no significant changes in maximum flow rate, voided volume, or AUA symptom score after one year of finasteride 2.5 mg daily therapy. PSA increased significantly, p < .01, after one year of finasteride 2.5 mg daily, 2.0 +1.4 ng/ml, when compared to finasteride 5 mg daily, 1.4+ 1.0 ng/ml.
        
        
          Conclusions
          The daily dose of finasteride can be reduced to 2.5 mg daily without significant effect on subjective and objective measures of urinary obstruction. Although statistically significant increases in PSA are noted when reducing the daily finasteride dose from 5 mg to 2.5 mg, the clinical significance of a mean .6 ng/ml increase in PSA is questionable.
Compound 525876: N,N-Dimethyl-N'-(3-methoxyphenyl)-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-methoxyphenyl)-N,N,2-trimethylpropanimidamide. Molecular Formula: C13H20N2O. Molecular Weight: 220.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529378: 4,6-Diethyl-1,2,3,5-tetrathiane

Chemical compound data from PubChem database. IUPAC Name: 4,6-diethyl-1,2,3,5-tetrathiane. Molecular Formula: C6H12S4. Molecular Weight: 212.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2012 Uniform Reporting System (URS) Tables for Washington

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E399867-T1: [Translated] EPOXY HYDROLASE FROM ASPERGILLUS

The invention concerns proteins of fungal origin having an epoxide hydrolase activity, such as those obtained in essentially pure form by extraction from fungi cells, or by culturing in host cells transformed by a nucleotide sequence coding for said fungal proteins. The invention also concerns the uses thereof, in particular for implementing methods for preparing enantiopure epoxides and/or diols.
Chicago: Drug-Related Emergency Department Visits, 2004-2011 - All Visits

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits in the Chicago metropolitan area, covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving all forms of drug misuse or abuse plus visits resulting from adverse reaction, accidental ingestion, suicide attempts, and visits where patients were seeking detoxification services. These estimates are useful for looking at overall levels of drug involvement in ED visits.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Substance Use among 12th Grade Aged Youths, by Dropout Status

for example, 12th grade aged dropouts were more likely to be current cigarette users (55.9 vs. 20.2 percent), be alcohol users (41.1 vs. 33.7 percent), engage in binge alcohol use (31.8 vs. 22.1 percent), engage in any illicit drug use (31.4 vs. 18.1 percent), engage in marijuana use (27.5 vs. 15.6 percent), and engage in nonmedical use of prescription-type drugs (9.5 vs. 4.6 percent).
Compound 529217: Cyclopentanol, DMTBS

Chemical compound data from PubChem database. IUPAC Name: tert-butyl-cyclopentyloxy-dimethylsilane. Molecular Formula: C11H24OSi. Molecular Weight: 200.39. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Rhode Island (RI)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Rhode Islandoverall and for substate regions within Rhode Island. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Patent AT-E401718-T1: [Translated] COMMUNICATIONS SYSTEM HAVING A DEVICE FOR RECEIVING DATA FROM A VARIETY OF MEASURING OR CONTROL DEVICES

Apparatus ( 3 ) for receiving data from at least one control or measuring device ( 1 ), comprising, a device interface ( 27 ) for communication of data between the apparatus ( 3 ) and said device ( 1 ), a central processor ( 23 ) for controlling data flow in the apparatus ( 3 ), and an input/output interface ( 29 ) for communicating with an external communications network, whereby information from one or more devices ( 1 ) can be communicated to a central data distribution network ( 9 ).
Compound 530473: m-Toluic acid, 1-adamantylmethyl ester

Chemical compound data from PubChem database. IUPAC Name: 1-adamantylmethyl 3-methylbenzoate. Molecular Formula: C19H24O2. Molecular Weight: 284.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.